Neoadjuvant chemotherapy in gynaecological cancers - Implications for staging

Area of Science:

• Gynecologic Oncology
• Surgical Oncology
• Medical Oncology

Background:

• Advanced gynecological cancers present significant management challenges.
• Neoadjuvant chemotherapy is a strategy to reduce tumor burden before definitive local treatment.
• Its role in ovarian and cervical cancers is under ongoing investigation.

Purpose of the Study:

• To evaluate the efficacy and outcomes of neoadjuvant chemotherapy followed by surgery in advanced gynecological cancers.
• To compare survival and morbidity with primary debulking surgery followed by chemotherapy.

Main Methods:

• Review of non-randomized and randomized studies on neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
• Analysis of outcomes including optimal debulking rates, operative morbidity, overall survival, and progression-free survival.
• Examination of neoadjuvant chemotherapy's impact on stage IB2-IIA cervix cancer survival.

Main Results:

• Neoadjuvant chemotherapy followed by interval debulking surgery is a reasonable approach for inoperable advanced ovarian cancer.
• Optimal debulking (no visible tumor) achieved in approximately 40% of patients with reduced morbidity.
• Overall and progression-free survival are comparable to primary debulking surgery followed by chemotherapy.
• Improved survival observed for stage IB2-IIA cervix cancer patients receiving neoadjuvant chemotherapy before surgery.

Conclusions:

• Neoadjuvant chemotherapy followed by surgery is an effective strategy for select advanced gynecological cancers.
• This approach facilitates optimal debulking and offers comparable survival benefits with potentially reduced morbidity.
• Further research, including randomized trials of short-course neoadjuvant chemotherapy prior to chemoradiation, is ongoing.